Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESQ Phase III Eribulin vs S-1 in HER2-negative Metastatic Breast Cancer
jRCTs011180026Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer and breast cancer (BC) comparing Eribulin with S-1 (2 arms). Primary endpoint: Health-related Quality of Life (HRQoL). Started Jun 2016; status: completed.
02
Drugs
eribulintegafur
03
Conditions
breast cancerbreast cancer (BC)
Beyond the preview
Go deeper on jRCTs011180026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011180026.